University System of Maryland

Yongjun Guan

George K Lewis

Anthony DeVico

Hanping Feng

Mohammad Sajadi

Yongrong Zhang

Zhiyong Yang

Marzena Pazgier

Tongyun Liu

Lianfa Shi

Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity totoxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VH peptide monomers, linked groups of VH peptide monomers, VH peptide monomers joined to antibody Fc domains, and VH peptide monomers joined to IgG antibodies.

Tetra-specific, octameric binding agents and antibodies againsttoxin A and toxin B for treatment ofinfection

Fusion proteins comprising a portion of the HIV-1 Env protein (gp120 and gp140) and single-chain fragment V regions (ScFv) of an enhancing antibody that exhibits binding specificity for HIV-1 Env protein are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection, as well as methods of generating an immune response using the fusion proteins.

Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb

The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).

Rapid expression cloning of human monoclonal antibodies from memory B cells

Growing community of inventors

Clarksville, MD, United States of America

Yongjun Guan